Amedisys (NASDAQ:AMED) Given “Neutral” Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Amedisys (NASDAQ:AMED) in a report published on Thursday, Benzinga reports. They currently have a $101.00 price target on the health services provider’s stock.

Several other equities research analysts also recently weighed in on AMED. William Blair downgraded shares of Amedisys from an outperform rating to a market perform rating in a research note on Monday, July 1st. StockNews.com raised shares of Amedisys from a hold rating to a buy rating in a research note on Saturday, May 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Hold and an average price target of $100.67.

Amedisys Stock Performance

Shares of NASDAQ:AMED opened at $97.75 on Thursday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. Amedisys has a 52 week low of $89.55 and a 52 week high of $98.46. The firm’s fifty day moving average is $94.81 and its 200-day moving average is $93.79.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The business had revenue of $571.41 million for the quarter, compared to analyst estimates of $565.38 million. Amedisys had a net margin of 4.02% and a return on equity of 12.56%. Amedisys’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.00 earnings per share. Research analysts forecast that Amedisys will post 4.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Amedisys

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Amedisys by 0.4% during the third quarter. Vanguard Group Inc. now owns 3,241,160 shares of the health services provider’s stock worth $302,724,000 after acquiring an additional 12,137 shares in the last quarter. Alpine Associates Management Inc. increased its position in shares of Amedisys by 23.0% during the fourth quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after acquiring an additional 237,600 shares in the last quarter. Park West Asset Management LLC increased its position in shares of Amedisys by 8.0% during the fourth quarter. Park West Asset Management LLC now owns 812,069 shares of the health services provider’s stock worth $77,195,000 after acquiring an additional 60,350 shares in the last quarter. Water Island Capital LLC increased its position in shares of Amedisys by 185.0% during the fourth quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock worth $67,559,000 after acquiring an additional 461,368 shares in the last quarter. Finally, Calamos Advisors LLC increased its position in shares of Amedisys by 11.6% during the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider’s stock worth $36,476,000 after acquiring an additional 41,220 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.